GLAXOSMITHKLINE PLC 4

Accession 0001387131-21-007179

$GSKCIK 0001235912other

Filed

Jul 5, 8:00 PM ET

Accepted

Jul 6, 4:38 PM ET

Size

30.0 KB

Accession

0001387131-21-007179

Form 4

Period: 2021-07-02

10% Owner

Transactions

Conversion
Common Stock
2021-07-02+1,505→ 33,316 total(indirect: See Footnote)
Conversion
Common Stock
2021-07-02+8,380→ 69,592 total(indirect: See Footnote)
Conversion
Common Stock
2021-07-02+635,646→ 732,583 total(indirect: See Footnote)
Conversion
Common Stock
2021-07-02+27,345→ 96,937 total(indirect: See Footnote)
Conversion
Series G Preferred Stock
2021-07-02−10,055,408→ 0 total(indirect: See Footnote)
→ Common Stock (635,646 underlying)
Conversion
Series C-2 Preferred Stock
2021-07-02−513,312→ 0 total(indirect: See Footnote)
→ Common Stock (12,979 underlying)
Conversion
Series D-2 Preferred Stock
2021-07-02−589,939→ 0 total(indirect: See Footnote)
→ Common Stock (14,917 underlying)
Conversion
Series E-2 Preferred Stock
2021-07-02−331,399→ 0 total(indirect: See Footnote)
→ Common Stock (8,380 underlying)
Conversion
Common Stock
2021-07-02+12,979→ 46,295 total(indirect: See Footnote)
Conversion
Common Stock
2021-07-02+14,917→ 61,212 total(indirect: See Footnote)
Purchase
Common Stock
2021-07-02$18.00/sh+275,000$4,950,000→ 1,007,583 total(indirect: See Footnote)
Conversion
Series F-2 Preferred Stock
2021-07-02−1,081,434→ 0 total(indirect: See Footnote)
→ Common Stock (27,345 underlying)
Conversion
Series B-2 Preferred Stock
2021-07-02−59,527→ 0 total(indirect: See Footnote)
→ Common Stock (1,505 underlying)

Footnotes (5)

[F1]Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.
[F2]The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
[F3]The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
[F4]The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
[F5]The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.

Documents

1 file

CVRx, Inc.

CIK 0001235912

Entity typeother

IncorporatedUnited Kingdom